Literature DB >> 17111269

Interfractional fluctuation of rectal dose in high dose rate brachytherapy for prostate cancer.

Hime Ishikawa1, Morio Sato, Shintaro Shirai, Kazushi Kishi, Yoshitaka Naya, Hisaki Tokunaga.   

Abstract

PURPOSE: The aim of the study was to explore the cause of the difference in the maximal rectal dose between the first and second high dose rate (HDR) brachytherapy applications by comparing the thickness of the anterior rectal wall.
MATERIALS AND METHODS: The rectal dose and the thickness of the anterior rectal wall were analyzed in 26 patients with prostate cancer. After undergoing external beam radiation treatment with a total isocenter dose of 50 Gy, they were treated with HDR brachytherapy of 7.5 Gy/fraction, two fractions daily. The interval between the first HDR brachytherapy session and the second was 5 h. The rectal doses were directly surveyed during irradiation of the HDR brachytherapy. Thickening of the anterior rectal wall was measured at the same level by axial computed tomography scans obtained before the first and second HDR brachytherapy applications.
RESULTS: The maximal surveyed rectal doses during the first and second HDR brachytherapy applications were 188 +/- 51 cGy and 220 +/- 35 cGy, respectively (P < 0.01). The fluctuation ratio exceeded 1 in each case. The thickness of the anterior rectal wall before the first and second HDR brachytherapy applications was 18.78 +/- 4.34 mm and 14.95 +/- 4.09 mm (P < 0.01), respectively. The fluctuation difference exceeded 0 in each case.
CONCLUSION: The different rectal dose is attributable to thinning of the anterior rectal wall. The total rectal dose is within the range of doses at risk of exerting a toxic effect on the rectum.

Entities:  

Mesh:

Year:  2006        PMID: 17111269     DOI: 10.1007/s11604-006-0079-1

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  26 in total

1.  High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial.

Authors:  Y Yoshioka; T Nose; K Yoshida; T Inoue; H Yamazaki; E Tanaka; H Shiomi; A Imai; S Nakamura; S Shimamoto; T Inoue
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-10-01       Impact factor: 7.038

2.  Clinical course of rectal bleeding following I-125 prostate brachytherapy.

Authors:  K Hu; K Wallner
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-05-01       Impact factor: 7.038

3.  Dosimetric and radiographic correlates to prostate brachytherapy-related rectal complications.

Authors:  B H Han; K E Wallner
Journal:  Int J Cancer       Date:  2001-12-20       Impact factor: 7.396

4.  Rectal dosimetric analysis following prostate brachytherapy.

Authors:  G S Merrick; W M Butler; A T Dorsey; J H Lief; H L Walbert; H J Blatt
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-03-15       Impact factor: 7.038

5.  Effect of post-implant edema on the rectal dose in prostate brachytherapy.

Authors:  F M Waterman; A P Dicker
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-10-01       Impact factor: 7.038

6.  Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis.

Authors:  K M Snyder; R G Stock; S M Hong; Y C Lo; N N Stone
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-06-01       Impact factor: 7.038

7.  Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer.

Authors:  Alvaro A Martinez; Gary Gustafson; José Gonzalez; Elwood Armour; Chris Mitchell; Gregory Edmundson; William Spencer; Jannifer Stromberg; Raywin Huang; Frank Vicini
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-06-01       Impact factor: 7.038

8.  Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.

Authors:  Junichi Hiratsuka; Yoshimasa Jo; Kenji Yoshida; Naomi Nagase; Masato Fujisawa; Yoshinari Imajo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-01       Impact factor: 7.038

9.  Probability of late rectal morbidity in 125I prostate brachytherapy.

Authors:  Frank M Waterman; Adam P Dicker
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-02-01       Impact factor: 7.038

10.  Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial.

Authors:  A Martinez; J Gonzalez; J Stromberg; G Edmundson; M Plunkett; G Gustafson; D Brown; D Yan; F Vicini; D Brabbins
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-12-01       Impact factor: 7.038

View more
  4 in total

1.  Radiation dose to rectum in high-dose-rate brachytherapy with a single implant and two fractions for prostate cancer, and its prediction by prostate volume.

Authors:  Noritaka Shimizu; Yasutaka Noda; Morio Sato; Shintaro Shirai; Nobuyuki Kawai; Shinji Harada; Takaki Sakamoto; Tadayoshi Nishioku
Journal:  Radiol Phys Technol       Date:  2014-07-18

2.  The impact of prostate volume changes during external-beam irradiation in consequence of HDR brachytherapy in prostate cancer treatment.

Authors:  Markus Karl Alfred Herrmann; Tammo Gsänger; Arne Strauss; Tereza Kertesz; Hendrik A Wolff; Hans Christiansen; Hilke Vorwerk; Clemens Friedrich Hess; Andrea Hille
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

3.  Gold marker displacement due to needle insertion during HDR-brachytherapy for treatment of prostate cancer: a prospective cone beam computed tomography and kilovoltage on-board imaging (kV-OBI) study.

Authors:  Markus K A Herrmann; Tereza Kertesz; Tammo Gsänger; Eugen Bloch; Gerhard Pollul; Mohamed Bouabdallaoui; Arne Strauss; Mareike Herrmann; Hans Christiansen; Hendrik A Wolff; Clemens F Hess; Andrea Hille
Journal:  Radiat Oncol       Date:  2012-02-20       Impact factor: 3.481

4.  Efficacy and safety of high-dose-rate brachytherapy of single implant with two fractions combined with external beam radiotherapy for hormone-naïve localized prostate cancer.

Authors:  Yasutaka Noda; Morio Sato; Shintaro Shirai; Kazushi Kishi; Takeshi Inagaki; Takeshi Mori; Isao Hara
Journal:  Cancers (Basel)       Date:  2011-09-14       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.